IL1B and COVID-19: To support these conclusions, indeed, it is notable that AIFA (Italian Medicines Agency) has recently authorized anakinra, an anti-IL-1β drug (already used for rheumatoid arthritis) for the treatment of patients affected by COVID-19, and other studies confirmed the efficacy of biologic drugs for the early comparison to COVID-19 clinical manifestation [199,200,201].